Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Profit After Tax (2016 - 2026)

Summit Therapeutics filings provide 13 years of Profit After Tax readings, the most recent being -$189.4 million for Q1 2026.

  • Quarterly Profit After Tax fell 201.09% to -$189.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Mar 2026, down 400.96% year-over-year, with the annual reading at -$1.1 billion for FY2025, 387.81% down from the prior year.
  • Profit After Tax hit -$189.4 million in Q1 2026 for Summit Therapeutics, up from -$219.2 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$14.7 million in Q2 2023 and bottomed at -$565.7 million in Q2 2025.
  • Average Profit After Tax over 5 years is -$128.5 million, with a median of -$56.3 million recorded in 2024.
  • The largest annual shift saw Profit After Tax tumbled 2434.82% in 2023 before it skyrocketed 91.98% in 2024.
  • Summit Therapeutics' Profit After Tax stood at -$19.2 million in 2022, then crashed by 90.17% to -$36.6 million in 2023, then crashed by 67.37% to -$61.2 million in 2024, then tumbled by 258.11% to -$219.2 million in 2025, then rose by 13.57% to -$189.4 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Profit After Tax are -$189.4 million (Q1 2026), -$219.2 million (Q4 2025), and -$231.8 million (Q3 2025).